United States Immunology Drugs Market is to reach USD 114.60 billion by 2034 | Market Size, Share, Trends, and Forecast (2025-2033) | Major Players-Eli Lilly and Company, AbbVie Inc., Novartis Pharmaceuticals Corporation | DataM Intelligence

Leander, Texas- The global immunology drugs market size was US$ 122.40 Billion in 2024 and is expected to reach US$ 262.01 Billion by 2033, growing at a CAGR of 8.8% during the forecast period 2025-2033. Market is driven by Rising autoimmune diseases, advanced biologics, growing geriatric population, increasing healthcare spending, and innovations in targeted immunotherapies drive growth

Download Free sample report:-https://www.datamintelligence.com/download-sample/immunology-drugs-market?pratik

Recent Industry Development in U.S market:

✅ The U.S. immunology drugs market was valued at USD 43.09 billion in 2024, and is projected to reach around USD 114.60 billion by 2034, growing at a CAGR of 10.28% (2025-2034).

✅ There is intensifying biosimilar competition due to patent expiry of blockbuster biologics. For example, over 30 biosimilars are approved in the U.S., and the FDA in 2024 approved "Otulfi," a biosimilar referencing Stelara.

✅ A shift in R&D is happening: drug developers are increasingly targeting novel immune pathways ( IL-6, IL-7, TYK2, FcRn) rather than broad immunosuppression, to design more precise immunology therapies.

✅In April 2025, Amgen received FDA approval for UPLIZNA (inebilizumab) for IgG4‐related disease.

✅ In February 2024, AbbVie acquired ImmunoGen, adding its lead antibody-drug conjugate (ELA‐HERE) to bolster its immuno-oncology / immunology pipeline.

✅ Lifileucel, a tumor-derived T-cell immunotherapy, was approved by the FDA in Feb 2024 for unresectable or metastatic melanoma.

Recent Industry Development in Japan market:

✅ Japan's immunology drugs market generated a revenue of USD 10,149.9 million in 2024, and is projected to grow to USD 19,238.7 million by 2030, at a CAGR of 11.3% (2025-2030).

✅ In 2024, Japan accounted for about 3.9% of the global immunotherapy drugs market.

✅ Among drug types in Japan, monoclonal antibodies (mAbs) are the largest revenue-generating class in 2024.

✅ Demographic tailwinds: Japan's aging population (with over 28% aged 65+) is driving demand for antibody‐based therapies, particularly for autoimmune diseases and cancer.

✅ Collaboration & innovation: For example, ImmunoGen entered a licensing / development deal with Takeda to commercialize its ADC (mirvetuximab soravtansine, ELA‐HERE) in Japan.

Key Investment:-

➠ Vertex Pharmaceuticals (U.S.): Acquired Alpine Immune Sciences in April 2024 for USD 4.9 billion. Alpine's lead assets include treatments for systemic lupus erythematosus (SLE) and lupus nephritis.

➠ Eli Lilly (U.S.): Bought Morphic Therapeutic in July 2024 for USD 3.2 billion to secure MORF-057, an oral α4β7 integrin inhibitor for inflammatory bowel disease (IBD).

➠ Biogen (U.S.): Acquired Human Immunology Biosciences (HI‐Bio) in May 2024 (deal value USD 1.8 billion including milestones) for felzartamab, a CD38‐targeting antibody for autoimmune kidney diseases.

➠ AltruBio: Raised USD 225 million in a Series B round (May 2024) to advance ALTB-268, a PSGL-1 agonist antibody for ulcerative colitis and other immunological diseases.

➠ Candid Therapeutics: Secured USD 376 million (Series B plus acquisitions) in 2024 to develop bispecific T-cell engagers targeting B-cell-driven autoimmune diseases.

➠ Alumis: Raised USD 259 million (Series C, March 2024) to push forward its TYK2 inhibitor (ESK-001) into Phase III for autoimmune disorders.

➠ Mirador Therapeutics: Launched in 2024 with USD 400 million in funding to develop precision immunology therapies for inflammatory and fibrotic diseases, using its "Mirador360" engine.

➠ Capstan Therapeutics: Raised USD 175 million in a Series B round (March 2024) to develop its in vivo CAR‐T therapy (CPTX2309) for autoimmune disorders.

➠ Lycia Therapeutics: Received USD 106.6 million in Series C funding (May 2024) to develop LYTAC (extracellular protein degrader) candidates for inflammatory and autoimmune diseases.

➠ Bain Capital + Bristol Myers Squibb (U.S.): In July 2025, Bain Capital put up USD 300 million to form a new independent company that will develop five immunology experimental drugs licensed from BMS (including a late-stage lupus therapy). BMS retains 20% equity.

➠ Johnson & Johnson (U.S.): Acquired Proteologix (Q1 2025) for USD 850 million, gaining access to bispecific antibody platforms for chronic immunoinflammatory diseases like lupus and psoriasis.

Benefits of AI for the Immunology Drugs Market

➠Accelerated drug discovery through AI-driven molecular modeling and predictive simulations.

➠Enhanced clinical trial design with AI predicting patient responses and optimizing protocols.

➠Personalized treatment recommendations using AI analysis of patient genetic and immunological data.

➠Faster identification of potential adverse effects and drug interactions.

➠Optimized supply chain management for immunology drugs through predictive AI analytics.

➠Automation of routine laboratory tasks, reducing human error and increasing efficiency.

➠Improved regulatory compliance with AI monitoring and reporting systems.

➠Advanced disease pattern analysis to guide research and therapeutic focus.

"Secure your 30% year-end discount - get this report before the offer expires."
:https://www.datamintelligence.com/buy-now-page?report=immunology-drugs-market?pratik ((Purchase 2 or more Repots and get 50% Discount)

Segmentation Analysis :

➠By Drug Class: Monoclonal antibodies dominate the market, driven by targeted therapies for autoimmune diseases and cancers. Antibody-drug conjugates are growing due to their precision and efficacy. Immunosuppressive medications maintain steady demand for organ transplant and autoimmune treatments. Interferon and cytokine therapies occupy a niche but critical segment, while other classes include emerging biologics and small-molecule immunomodulators.

➠By Indication: Rheumatoid arthritis represents the largest share, fueled by rising prevalence and biologic adoption. Psoriasis treatments follow, supported by new targeted therapies. Inflammatory bowel disease (IBD) is expanding rapidly due to early diagnosis and advanced biologics. Graft-versus-host disease (GVHD) holds a smaller but vital share, primarily in transplant care. Other indications, including multiple sclerosis and lupus, are niche yet witnessing steady growth from innovative therapies.

Regional Insights:

➠ North America: 48.5% of the global immunology drugs market in 2024. The region is the largest market, driven by advanced biologic adoption, strong R&D investment, a high prevalence of autoimmune and inflammatory diseases, and favorable reimbursement policies.
➠ Asia‐Pacific: Fastest‐growing region, with a CAGR of 7.7% in 2024.Growth is propelled by rising healthcare access, increasing autoimmune disease awareness, growing R&D in biologics, and strategic partnerships between global and local pharma firms. Key markets include China, Japan, India, and South Korea. In China especially, regulatory reforms, domestic biotech innovation, and increasing approvals support high uptake.

➠ Europe: Mature and significant market, contributing 34.5% of global market share in 2024. Backed by a strong biotech R&D ecosystem, robust regulatory frameworks, and increasing acceptance of biosimilars.

Growth drivers:

Rising prevalence of chronic immune-mediated diseases like cancer, autoimmune disorders, and inflammatory diseases.

Aging global population increasing demand for immunotherapies.

Advances in biotechnology including cell-based therapies, targeted antibodies, and personalized medicine approaches.

Expanding R&D pipelines with novel therapies and improved efficacy, safety, and convenience.

Growing adoption of biologics and next-generation drugs supported by favorable reimbursement policies.

Increasing healthcare infrastructure and awareness in emerging markets, especially Asia-Pacific.

Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/immunology-drugs-market?pratik

Key players:

Eli Lilly and Company, AbbVie Inc., Novartis Pharmaceuticals Corporation, Sun Pharmaceutical Industries, Inc., Johnson & Johnson, Genentech USA, Inc., Bristol-Myers Squibb Company, Sanofi, Pfizer Inc., and GlaxoSmithKline plc, among others.

Key highlights:

➠ Eli Lilly and Company
Eli Lilly is a strong immunology player with Taltz (ixekizumab), a monoclonal antibody targeting IL‐17A used for psoriasis, psoriatic arthritis, and other inflammatory conditions.
They also market Olumiant® (baricitinib), an oral JAK inhibitor approved for rheumatoid arthritis, atopic dermatitis, and other autoimmune disorders.
Lilly is actively strengthening its immunology pipeline: it acquired Dice Therapeutics (US$2.4 B) to add oral IL‐17 inhibitors, signaling a push into next-gen immunology therapies.

➠ AbbVie Inc.
AbbVie remains one of the dominant players in immunology. According to market‐analysis reports, it holds more than 18% of the global immunology market share, driven by its biologic portfolio.
Its strategy centers on newer immunology blockbusters: Skyrizi and Rinvoq
Importantly, Rinvoq has been extended in exclusivity (no generic competition) until 2037, securing long-term revenue potential.

➠ Novartis Pharmaceuticals Corporation
Novartis has built a broad immunology & dermatology portfolio. Its flagship biologic is Cosentyx , used for psoriasis, ankylosing spondylitis, and psoriatic arthritis.
Other key immunology drugs include Ilaris for autoinflammatory diseases, Xolair for urticaria/allergy, and Zortress/Certican for transplant immunology.
Novartis is also pushing innovation: it signed a US$5.7 billion licensing deal with Monte Rosa Therapeutics to develop immune-mediated disease drugs using small-molecule degraders.


Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?pratik

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insightsthrough pricing analysis, market share breakdowns, and competitive intelligence. Thecompany specializes in strategic reports that guide businesses in high-growth sectors suchas nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter,LinkedIn and Facebook.

This release was published on openPR.